Mouse study identifies new target for human accelerated ageing syndrome
Scientists have identified a potential therapeutic target in the devastating genetic disease Hutchinson-Gilford progeria syndrome (HGPS), which is characterised by premature ageing.
The study – funded by the MRC, Wellcome and Cancer Research UK – provides preclinical data showing that chemical inhibition or genetic deregulation of the enzyme N-acetyltransferase 10 (NAT10) leads to significant health and lifespan gains in a mouse model of HGPS.
HGPS is a rare condition: patients have an average life expectancy of around 15 years, suffering a variety of symptoms including short stature, low body weight, hair loss, skin thickening, problems with fat storage, osteoporosis, and cardiovascular disease, typically dying of a heart attack.
Please sign up to our weekly newsletter to keep up to date: